Cancer最新文献

{"title":"Correction to “Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis”","authors":"","doi":"10.1002/cncr.70003","DOIUrl":"10.1002/cncr.70003","url":null,"abstract":"<p>Beaussant Y, Tarbi E, Nigam K, et al. Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: qualitative analysis. <i>Cancer</i>. 2024;130(7):1147-1157. doi:10.1002/cncr.35024</p><p>In addition to the affiliations cited in the published article, Michael Ljuslin is affiliated with the Department of Psychosocial Oncology and Palliative Care at the Dana–Farber Cancer Institute in Boston, Massachusetts.</p><p>Moreover, Ljuslin's ORCID identifier, https://orcid.org/0000-0002-2386-1749, was inadvertently not included.</p><p>We apologize for these errors.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 15","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144647225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate cancer incidence and outcomes among Vietnam veterans receiving care in the Veterans Health Administration","authors":"Ashley-Marie Y. Green-Lott MD,&nbsp;Ananta Wadhwa BS,&nbsp;Anissa V. Bailey MPH,&nbsp;Lorna Kwan MPH,&nbsp;Candace L. Haroldsen MSPH,&nbsp;Jeremy B. Shelton MD, MSHS,&nbsp;Michael S. Lewis MD,&nbsp;David O. Beenhouwer MD,&nbsp;Karim Chamie MD,&nbsp;Brent S. Rose MD,&nbsp;Kara N. Maxwell MD, PhD,&nbsp;Nicholas G. Nickols MD, PhD,&nbsp;Kosj Yamoah MD, PhD,&nbsp;Michael J. Kelley MD,&nbsp;Timothy R. Rebbeck PhD,&nbsp;Martin Schoen MD, MPH,&nbsp;Matthew B. Rettig MD,&nbsp;Hari S. Iyer ScD,&nbsp;Isla P. Garraway MD, PhD","doi":"10.1002/cncr.70007","DOIUrl":"10.1002/cncr.70007","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Agent Orange exposure (AOE) is considered a presumptive cause of prostate cancer (PCa) in the Veterans Affairs (VA) population; however, cohort studies reported inconsistent associations of AOE and PCa incidence and outcomes. In this nationwide cohort study, Vietnam veterans who received VA care were evaluated for associations of AOE and PCa incidence and adverse outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Vietnam veterans 17–25 years old during military service (1962–1971) who received VA health care between 2005 and 2020 were stratified by presumptive AOE assigned by the VA and followed until death from any cause or censoring on September 31, 2023. Multivariable Cox models permitted estimation of adjusted hazard ratios (aHRs) of AOE with PCa incidence, de novo metastasis (DNM), any metastasis, metastatic castration-resistant PCa (mCRPC), all-cause mortality (ACM), or PCa-specific mortality (PCSM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 2.6 million Vietnam veterans at risk for PCa, 779,472 (30%) had AOE. Compared to unexposed veterans, AOE veterans had higher PCa risk (aHR, 1.15; 95% confidence interval [CI], 1.15–1.16), higher DNM (aHR, 1.17; 95% CI, 1.16–1.17), any metastasis (aHR, 1.17; 95% CI, 1.16–1.17), mCRPC (aHR, 1.17; 95% CI, 1.16–1.17), ACM (aHR, 1.41; 95% CI, 1.41–1.42), and PCSM (aHR, 1.17; 95% CI, 1.16–1.17) in adjusted models. Sensitivity analyses suggested robustness of association between AOE and all-cause mortality, but selection bias could explain associations with PCa outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Presumptive AOE was associated with higher PCa incidence, mortality, and adverse outcomes. Although associations may not be causal, AOE may predict worse PCa outcomes in the Veterans Affairs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 15","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144657731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.35924","DOIUrl":"10.1002/cncr.35924","url":null,"abstract":"&lt;p&gt;For patients with locally advanced esophageal cancer who have a clinical complete response rate after neoadjuvant chemoradiotherapy, active surveillance could be introduced as an alternative approach to standard surgery during patient counseling based on the results of a trial showing the noninferiority of active surveillance to standard surgery.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The phase 3, multicenter, cluster-randomized, noninferiority Surgery as Needed for Oesophageal Cancer (SANO) trial included both an intention-to-treat analysis, which included 776 patients (275 had a clinical complete response and were assigned to active surveillance [&lt;i&gt;n&lt;/i&gt; = 156] or standard surgery [&lt;i&gt;n&lt;/i&gt; = 118]), and a modified intention-to-treat analysis (allowing for patients with a complete response to cross over into the active surveillance group), which included 309 patients (198 underwent active surveillance, and 111 underwent standard surgery). Most of these patients had adenocarcinoma (147 in the active surveillance cohort and 84 in the surgery cohort), which was followed by squamous cell carcinoma (47 and 32 patients, respectively) and other types of carcinomas (four patients in each cohort). &lt;i&gt;Clinical complete response&lt;/i&gt; was defined as no tumor detected based on endoscopic biopsy, ultrasound, or positron emission tomography–computed tomography (PET-CT). All patients were at least 18 years old, had locally advanced esophageal cancer, and were treated with curative intent. No patients were excluded based on comorbidities or performance status.&lt;/p&gt;&lt;p&gt;After a minimum 2-year follow-up, overall survival (OS) with active surveillance was noninferior to OS with standard surgery (71%) after the modified intention-to-treat analysis. It remained noninferior in the intention-to-treat analysis (75%), with no significant differences in OS between the modified intention-to-treat analysis (hazard ratio [HR], 1.14; 95% CI, 0.74–1.78) and the intention-to-treat analysis (HR, 0.83; 95% CI, 0.53–1.31).&lt;/p&gt;&lt;p&gt;According to a patient-reported quality-of-life assessment, patients who underwent active surveillance had significantly better global health-related quality of life than those who underwent surgery at both 6 months (increase of 10.4 points, &lt;i&gt;p&lt;/i&gt; = .001) and 9 months (increase of 8.5 points, &lt;i&gt;p&lt;/i&gt; = .009). No significant differences between the two cohorts in global health-related quality of life were seen at 12 months.&lt;/p&gt;&lt;p&gt;The lead author of the study, Berend J. van der Wilk, MD, PhD, a surgical resident in the Department of Surgery at the Erasmus MC Cancer Institute of the University Medical Centre in Rotterdam, the Netherlands, says that the results suggest that oncologists consider organ-sparing active surveillance for their patients with locally advanced esophageal cancer.&lt;/p&gt;&lt;p&gt;“If you proceed with active surveillance, please be sure to perform clinical response evaluations according to SANO protocol,” he emphasizes. This includes evaluating the cli","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 14","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35924","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144647397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"US FDA approves pembrolizumab as first-line treatment for patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.35925","DOIUrl":"10.1002/cncr.35925","url":null,"abstract":"<p>The US Food and Drug Administration (FDA) granted traditional approval of adding pembrolizumab to trastuzumab and standard chemotherapy (fluoropyrimidine- and platinum-containing chemotherapy) as a first-line treatment for patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) ≥1.<span>¹</span></p><p>The approval comes on the heels of the FDA’s accelerated approval on May 5, 2021, of the regimen in this setting based on the first interim analysis of the KEYNOTE-811 trial<span>²</span> and a subsequent amendment to this accelerated approval in November 2023 restricting its use to only patients whose tumors express PD-L1 with a CPS ≥1 according to an FDA-approved test.<span>³</span></p><p>KEYNOTE-811 is a phase 3, multicenter trial including 698 patients with HER2-positive advanced gastric or GEJ carcinoma who were randomized 1:1 to pembrolizumab (200 mg) or a placebo (each combined with trastuzumab and standard chemotherapy [fluoropyrimidine- and platinum-containing chemotherapy]) every 3 weeks for up to 35 cycles or until disease progression. Most of the patients in the trial had tumors that expressed PD-L1 with a CPS ≥1 (594 of 698 or 85%).</p><p>The traditional approval was based on the updated analyses of the trial, which showed significant improvements in progression-free survival (PFS) and overall survival (OS) for patients treated with the addition of pembrolizumab to trastuzumab and standard chemotherapy versus the placebo with trastuzumab and standard chemotherapy. For those patients making up the majority of the cohort (i.e., those with tumors expressing PD-L1 with a CPS ≥1), the median PFS was 10.9 and 7.3 months for the pembrolizumab and placebo groups, respectively; this represents a reduction in disease progression of 28% (hazard ratio [HR], 0.72; 95% CI, 0.60–0.87). The median OS was 20.1 and 15.7 months, respectively; this represents a reduction in the risk of death of 21% (HR, 0.79; CI, 0.66–0.95).<span>^{4, 5}</span></p><p>Michael Gibson, MD, PhD, associate professor of medicine and director of Translational Research for Esophagogastric Cancer at the Vanderbilt University Medical Center, Nashville, Tennessee, gave an emphatic “yes” to whether the approval adds a new and needed treatment in this setting. “It is the first indication for combining immunotherapy with a targeted agent in this population,” he says.</p><p>He notes that current trials are underway to evaluate the combination of immunotherapy with another recently approved targeted agent, zolbetuximab, for patients whose tumors express CLDN18.2.<span>⁶</span></p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 14","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35925","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144647398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of GemCap for pancreatic ductal adenocarcinoma","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.35923","DOIUrl":"10.1002/cncr.35923","url":null,"abstract":"&lt;p&gt;Results reported in the ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine alone for patients with pancreatic ductal adenocarcinoma (PDAC). These patients were not safe candidates for or did not wish to take modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX). The results were published in the &lt;i&gt;Journal of Clinical Oncology&lt;/i&gt;.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;At a median follow-up of 104 months, patients treated with GemCap had an improvement in OS in comparison with those treated with gemcitabine alone (31.6 vs. 28.4 months); this represents a 17% lower risk of death (hazard ratio [HR], 0.83; 95% CI, 0.71–0.98; &lt;i&gt;p&lt;/i&gt; = .031).&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; In a multivariable analysis, patients treated with GemCap had a 20% lower risk of death than those treated with gemcitabine alone (HR, 0.80; 95% CI, 0.68–0.95; &lt;i&gt;p&lt;/i&gt; = .01).&lt;/p&gt;&lt;p&gt;The median relapse-free survival with GemCap (21.3 months) versus gemcitabine alone (18.3 months) represents a 35% reduction in the risk of disease progression (HR, 0.85; 95% CI, 0.72–1.00; &lt;i&gt;p&lt;/i&gt; = .053).&lt;/p&gt;&lt;p&gt;The phase 3, open-label, multicenter ESPAC4 trial included 732 adults (≥18 years old) randomly assigned to gemcitabine alone (&lt;i&gt;n&lt;/i&gt; = 367) or GemCap (&lt;i&gt;n&lt;/i&gt; = 365) after complete macroscopic resection of PDAC. Patients were stratified by resection margin status (R0 or R1) and country of participation. Prior results at 43.2 months showed similar OS outcomes with median OS times of 28 and 25.5 months for patients treated with GemCap and gemcitabine alone, respectively; this represents an 18% reduced risk of death (HR, 0.82; 95% CI, 0.68–0.98; &lt;i&gt;p&lt;/i&gt; = .32).&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;An exploratory analysis in the current study found subgroups of patients (R0 status and negative lymph nodes) for whom GemCap may be particularly beneficial in comparison to gemcitabine alone.&lt;/p&gt;&lt;p&gt;For R0 status, the analysis showed that patients treated with GemCap had a significant improvement in median survival in comparison with those treated with gemcitabine alone (49.9 vs. 32.2 months); this represents a 37% reduction in the risk of death (HR, 0.63; 95% CI, 0.47–0.84; &lt;i&gt;p&lt;/i&gt; = .002). No significant difference was seen in patients with R1 status who were treated with GemCap compared to those treated with gemcitabine alone (25.9 vs. 25.5 months, &lt;i&gt;p&lt;/i&gt; = .28).&lt;/p&gt;&lt;p&gt;Negative lymph nodes also were associated with significantly higher estimated 5-year survival in patients treated with GemCap compared to those treated with gemcitabine alone (59% vs. 53%); this represents a 37% reduction in the risk of death (HR, 0.63; 95% CI, 0.41–0.98; &lt;i&gt;p&lt;/i&gt; = .04).&lt;/p&gt;&lt;p&gt;Researchers further explored estimated survival rates of patients treated with GemCap compared to those treated with gemcitabine alone by subgrouping the patients by eligibility status for inclusion in the PRODIGE24 trial. The PRODIGE24","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 14","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35923","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144647396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are transplant strategies in relapsed myeloma relevant in the cellular treatment era?","authors":"Despina Fotiou MD, PhD,&nbsp;Efstathios Kastritis MD, PhD","doi":"10.1002/cncr.70005","DOIUrl":"10.1002/cncr.70005","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 14","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144612020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of body composition in the development of diabetes mellitus among childhood cancer survivors, and novel intervention strategies to mitigate diabetes risk","authors":"Rusha Bhandari MD, MS,&nbsp;Yue Liao MPH, PhD,&nbsp;Ke Ma MD, PhD","doi":"10.1002/cncr.35977","DOIUrl":"10.1002/cncr.35977","url":null,"abstract":"<p>The growing population of childhood cancer survivors (CCSs) experiences a large burden of comorbidities, including a markedly increased risk of diabetes mellitus. Among CCSs, prediabetes and diabetes are important risk factors for subsequent cardiovascular disease, which is a leading cause of premature death in this patient population. The mechanisms underlying their development are multifactorial, and may differ from those in the general population. Emerging evidence from preclinical and clinical studies suggests that treatment-related alterations in body composition, specifically sarcopenic obesity, the aging-related loss of skeletal muscle mass with a simultaneous increase in adipose tissue mass, are a key contributory factor. Both skeletal muscle and adipose tissue are important endocrine organs involved in maintaining glucose homeostasis, with tissue crosstalk that can be disrupted by chemotherapy and radiation exposures. CCSs are particularly vulnerable to these effects as a result of receipt of cancer treatment during key periods of physiologic development, when organs are still maturing and there is peak muscle growth. Lifestyle modifications, which are a first-line intervention to improve muscle health and mitigate diabetes risk, have historically been difficult to implement long term. This review summarizes the current understanding of the impact of cancer and its treatment on muscle and adipose tissue by identifying important knowledge gaps and drawing on translational insights from preclinical models. Furthermore, it highlights opportunities to leverage contemporary digital care platforms to improve the early detection of diabetes and facilitate meaningful, sustainable lifestyle interventions to improve muscle health and decrease diabetes risk in the growing, at-risk population of CCSs.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 14","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144612019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic staging for advanced breast cancer: A biological reevaluation of de novo Stage IV metastatic disease","authors":"Benjamin O. Anderson MD, FACS","doi":"10.1002/cncr.35975","DOIUrl":"10.1002/cncr.35975","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 14","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144612021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic transplantation provides added benefit to FMS-like tyrosine kinase 3 (FLT3) inhibitors for both low-intensity and high-intensity regimens in FLT3-mutated acute myeloid leukemia","authors":"Pamela S. Becker MD, PhD","doi":"10.1002/cncr.35973","DOIUrl":"10.1002/cncr.35973","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 14","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144611960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The hidden economic burden of cancer caring","authors":"Lan Gao PhD,&nbsp;Shalika Bohingamu Mudiyanselage MHHSM,&nbsp;Anna Ugalde PhD,&nbsp;Jennifer J. Watts MCOm (Ec),&nbsp;Hannah Jongebloed MEd&DevPsych,&nbsp;Sangeetha Thomas PhD,&nbsp;Neha Das MHE,&nbsp;Andrew Lyall GradCert (SpecEd)&Dip (Teach),&nbsp;Natalie Winter PhD,&nbsp;Stephanie Cowdery PhD,&nbsp;Nikki McCaffrey PhD,&nbsp;Victoria White PhD,&nbsp;Patricia M. Livingston PhD","doi":"10.1002/cncr.35970","DOIUrl":"10.1002/cncr.35970","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Advances in clinical cancer care have increased the number of survivors, which has impacted informal caregiving. This study estimates the annual opportunity cost of informal cancer care and quantifies the gap in the quality adjusted life expectancy (QALE).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Informal cancer carers by sex and two age groups (15–64 years old and 65 years old and over) from the Australian Bureau of Statistics (ABS), Survey of Disability, Ageing and Carers (SDAC) from 2003 to 2022 were used to estimate the annual opportunity costs of informal cancer care in 2022 and predict future costs. Costs were based on an hourly wage rate, and the QALE were calculated by combining health-related quality of life (HRQOL) with life expectancy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In 2022, there were 59,100 informal cancer carers (61% female, 61% were above 65 years). The average time for informal cancer care was 28.6 hours per week. The average informal care cost was $60,853 per carer, and the cost is estimated to rise by 11% in 2025 and 30% in 2028. The QALE loss ranges from 1.8 to 5.4 months per year of caring, depending on age group and sex.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The time spent caring for people living with cancer by informal carers is significant. Recognizing and rigorously investigating the role of informal cancer carers in reducing the burden on the formal care sector and improving the quality of life of people living with cancer is essential to understanding the impact and significance of caring, which will facilitate impactful policy changes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 14","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35970","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144582072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}